NoVel Antimicrotubule Agents
Journal of Medicinal Chemistry, 2006, Vol. 49, No. 26 7825
(
22) Bergmann, E. D.; Rabinovitz, M.; Glily, S. A ring enlargement in
(40) Bai, R.; Roach, M. C.; Jayaram, S. K.; Barkoczy, J.; Pettit, G. R.;
Luduena, R. F.; Hamel, E. Differential effects of active isomers,
segments, and analogs of dolastatin 10 on ligand interactions with
tubulin. Correlation with cytotoxicity. Biochem. Pharmacol. 1993,
45, 1503-1515.
(41) Bai, R. L.; Pettit, G. R.; Hamel, E. Binding of dolastatin 10 to tubulin
at a distinct site for peptide antimitotic agents near the exchangeable
nucleotide and vinca alkaloid sites. J. Biol. Chem. 1990, 265, 17141-
17149.
the 9,10-dihydroanthracene series. Tetrahedron Suppl. 1966, 8, 141-
148.
(23) Weitz, E. U¨ ber einige Anthronabk o¨ mmlinge. Liebigs Ann. Chem.
1919, 418, 29-35.
(
24) Rappoport, Z.; Apeloig, Y.; Greenblatt, J. Vinylic cations from
solvolysis. 29. Solvolysis of 9-(R-bromoarylidene)anthrones as a
probe to the reactivity-selectivity relationship in solvolysis reactions.
J. Am. Chem. Soc. 1980, 102, 3837-3848.
(25) M u¨ ller, K.; G u¨ rster, D.; Piwek, S.; Wiegrebe, W. Antipsoriatic
(42) Carruthers, W.; Douglas, A. G.; Hill, J. Synthesis of naphtho[2,3-
b]thiophen. J. Chem. Soc. 1962, 704-708.
anthrones with modulated redox properties. 1. Novel 10-substituted
1
,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase.
(43) M u¨ ller, K.; Breu, K. 10-omega-phenylalkyl-9(10H)-anthracenones
as inhibitors of keratinocyte growth with reduced membrane damag-
ing properties. Bioorg. Med. Chem. Lett. 1998, 8 (22), 3211-3216.
(44) Schaltegger, A.; Steiger, W. Darstellung von 10-Alkylderivaten des
1,8-Dihydroxy-9(10H)-anthracenons (Dithranol). Arch. Pharm. 1986,
319, 575-576.
J. Med. Chem. 1993, 36 (25), 4099-4107.
(
(
(
(
26) Dimmel, D. R.; Shepard, D. Regioselective alkylation of anthra-
hydroquinone and anthrone in water with quinonemethides and other
alkylating agents. J. Org. Chem. 1982, 47, 22-29.
27) Lozzio, C. B.; Lozzio, B. B. Human chronic myelogenous leukemia
cell-line with positive philadelphia chromosome. Blood 1975, 45,
(45) Venkateswarlu, S.; Raju, M. S.; Subbaraju, G. V. Synthesis and
biological activity of isoamoenylin, a metabolite of Dendrobium
amoenum. Biosci. Biotechnol. Biochem. 2002, 66 (10), 2236-2238.
(46) Figad e` re, B.; Chaboche, C.; Franck, X.; Peyrat, J.-F.; Cav e´ , A.
Carbonyl reduction and functionalized aldehydes and ketones by tri-
321-334.
28) Lawrence, N. J.; Rennison, D.; Woo, M.; McGown, A. T.; Hadfield,
J. A. Antimitotic and cell growth inhibitory properties of combreta-
statin A-4-like ethers. Bioorg. Med. Chem. Lett. 2001, 11, 51-54.
29) Scudiero, D. A.; Shoemaker, R. H.; Paull, K. D.; Monks, A.; Tierney,
S.; Nofziger, T. H.; Currens, M. J.; Seniff, D.; Boyd, M. R. Evaluation
of a soluble tetrazolium/formazane assay for cell growth and drug
sensitivity in culture using human and other tumor cell lines. Cancer
Res. 1988, 48, 4827-4833.
n-butyltin hydride and SiO . J. Org. Chem. 1994, 59, 7138-7141.
2
(47) Kr o¨ hnke, F.; Schmeiss, H.; Gottstein, W. U¨ ber Enolbetaine, VIII.
Mitteil.: Umsetzungen mit Benzyl- und Cinnamoylhalogeniden zu
Phen a¨ thyl- und Homocinnamoyl-pyridiniumsalzen. Chem. Ber. 1951,
84, 131-138.
(30) Schmidt, M.; Lu, Y.; Parant, J. M.; Lozano, G.; Bacher, G.; Beckers,
(48) Guziec F. S., Jr.; Wei, D. Convenient halodeamination and hydro-
deamination of primary amines. J. Org. Chem. 1992, 57, 3772-
3776.
(49) Rychener, M.; Steiger, W.; Krebs, A. [Senecioyldithranol and beta-
carbethoxypropionyldithranol: synthesis and glucose-6-phosphate
dehydrogenase inhibition of two new 10-acyl derivatives of the
antipsoriatic, dithranol]. Pharm. Acta HelV. 1988, 63, 111-116.
(50) Amedio J. C., Jr.; Sunay, U. B.; Repic, O. Metalated aromatic
carboxylic acids: improved synthesis of SDZ HUL412. Synth.
Commun. 1995, 25, 667-680.
(51) Biel, J. H.; Drukker, A. E.; Mitchell, T. F.; Sprengeler, E. P.; Nuhfer,
P. A.; Conway, A. C.; Horita, A. Central stimulants. Chemistry and
structure-activity relationships of aralkyl hydrazines. J. Am. Chem.
Soc. 1959, 81, 2805-2813.
(52) Kruse, L. I.; Kaiser, C.; DeWolf, W. E., Jr.; Frazee, J. S.; Garvey,
E.; Hilbert, E. L.; Faulkner, W. A.; Flaim, K. E.; Sawyer, J. L.;
Berkowitz, B. A. Multisubstrate inhibitors of dopamine beta-
hydroxylase. 1. Some 1-phenyl and 1-phenyl-bridged derivatives of
imidazole-2-thione. J. Med. Chem. 1986, 29 (12), 2465-2472.
Waf1
Kip1
T.; Fan, Z. Differential roles of p21
and p27
in modulating
chemosensitivity and their possible application in drug discovery
studies. Mol. Pharmacol. 2001, 60, 900-906.
(
31) Dumontet, C.; Jaffrezou, J. P.; Tsuchiya, E.; Duran, G. E.; Chen,
G.; Derry, W. B.; Wilson, L.; Jordan, M. A.; Sikic, B. I. Resistance
to microtubule-targeted cytotoxins in a K562 leukemia cell variant
associated with altered tubulin expression and polymerization. Bull.
Cancer 2004, 91 (5), 81-112.
(
32) Dumontet, C.; Sikic, B. I. Mechanism of action of and resistance to
antitubulin agents: microtubule dynamics, drug transport, and cell
death. J. Clin. Oncol. 1999, 3, 1061-1070.
(
33) Fardel, O.; Lecureur, V.; Guillouzo, A. The P-glycoprotein multidrug
transporter. Gen. Pharmacol. 1996, 27, 1283-1291.
(34) Cole, S. P.; Deeley, R. G. Multidrug resistance mediated by the ATP-
binding cassette transporter protein MRP. Bioessays 1998, 20, 931-
940.
(
35) Verrills, N. M.; Kavallaris, M. Improving the targeting of tubulin-
binding agents: lessons from drug resistance studies. Curr. Pharm.
Des. 2005, 11 (13), 1719-1733.
(
53) Schmidt, M.; Lu, Y.; Liu, B.; Fang, M.; Mendelsohn, J.; Fan, Z.
Differential modulation of paclitaxel-mediated apoptosis by p21waf1
and p27kip1. Oncogene 2000, 19, 2423-2429.
(
36) De Martino, G.; Edler, M. C.; La Regina, G.; Coluccia, A.; Barbera,
M. C.; Barrow, D.; Nicholson, R. I.; Chiosis, G.; Brancale, A.; Hamel,
E.; Artico, M.; Silvestri, R. New arylthioindoles: potent inhibitors
of tubulin polymerization. 2. Structure-activity relationships and
molecular modeling studies. J. Med. Chem. 2006, 49 (3), 947-954.
37) Kuo, C. C.; Hsieh, H. P.; Pan, W. Y.; Chen, C. P.; Liou, J. P.; Lee,
S. J.; Chang, Y. L.; Chen, L. T.; Chen, C. T.; Chang, J. Y. BPR0L075,
a novel synthetic indole compound with antimitotic activity in human
cancer cells, exerts effective antitumoral activity in vivo. Cancer Res.
(
54) Bacher, G.; Nickel, B.; Emig, P.; Vanhoefer, U.; Seeber, S.; Shandra,
A.; Klenner, T.; Beckers, T. D-24851, a novel synthetic microtubule
inhibitor, exerts curative antitumoral activity in vivo, shows efficiacy
toward multidrug-resistant tumor cells, and lacks neurotoxicity.
Cancer Res. 2001, 61, 392-399.
(
(
(
(
(
(
55) Shelanski, M. L.; Gaskin, F.; Cantor, C. R. Microtubule assembly in
the absence of added nucleotides. Proc. Natl. Acad. Sci. U.S.A. 1973,
2004, 64 (13), 4621-4628.
70, 765-768.
38) Mahboobi, S.; Pongratz, H.; Hufsky, H.; Hockemeyer, J.; Frieser,
M.; Lyssenko, A.; Paper, D. H.; Burgermeister, J.; Bohmer, F. D.;
Fiebig, H. H.; Burger, A. M.; Baasner, S.; Beckers, T. Synthetic
56) Vater, W.; B o¨ hm, K. J.; Unger, E. A simple method to obtain brain
microtubule protein poor in microtubule-associated proteins. Acta
Histochem. Suppl. 1986, 33, 123-129.
2-aroylindole derivatives as a new class of potent tubulin-inhibitory,
57) Gaskin, F.; Cantor, C. R.; Shelanski, M. L. Turbidimetric studies of
the in vitro assembly and disassembly of porcine neurotubules. J.
Mol. Biol. 1974, 89 (4), 737-755.
antimitotic agents. J. Med. Chem. 2001, 44 (26), 4535-4553.
39) Tahir, S. K.; Kovar, P.; Rosenberg, S.; Ng, S.-C. A rapid colchicine
competition-binding scintillation proximity assay using biotin-labeled
colchicine. Biotechniques 2000, 29, 156-160.
JM0605031